{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"735"},{"groupId":"OG001","spread":"159","value":"652"},{"groupId":"OG002","spread":"255","value":"736"},{"groupId":"OG003","spread":"223","value":"731"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Mean with standard deviation of the elimination of crizotinib at steady state by dose level.","dispersionType":"Standard Error","groups":[{"description":"PF-02341066 165 mg/m²/dose BID","id":"OG000","title":"Dose Level 3"},{"description":"PF-02341066 215 mg/m²/dose BID","id":"OG001","title":"Dose Level 4"},{"description":"PF-02341066 280 mg/m²/dose BID","id":"OG002","title":"Dose Level 5"},{"description":"PF-02341066 365 mg/m²/dose BID","id":"OG003","title":"Dose Level 6"}],"paramType":"MEAN","populationDescription":"Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hour post-dose","title":"Steady State Clearance of Crizotinib","type":"PRIMARY","unitOfMeasure":"mL/min/m2"}